Tris Pharma and FSC Labs enter Karbinal accord
Drug delivery specialist Tris Pharma and fellow USA-based privately-held company FSC Laboratories have signed a definitive licensing agreement for the commercialization of Karbinal ER (carbinoxamine maleate) extended-release oral suspension 4mg/5ml.
Under the terms of the exclusive accord, Tris will manufacture Karbinal ER using its proprietary OralXR+ technology and FSC will market the drug. FSC will pay Tris up to $20 million in fixed and sales-related milestones, as well as a significant double-digit royalty on net sales.
Karbinal ER, said to be the first sustained-release histamine receptor blocking agent indicated for the treatment of seasonal and perennial allergic rhinitis in children aged two and up, is expected to be available in pharmacies across the USA in time for the 2014 spring allergy season.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze